论文部分内容阅读
目的观察埃索美拉唑三联疗法根除幽门螺旋杆菌(Helieobacter pylori,HP)感染消化性溃疡(Peptic Ulcer,PU)的临床疗效。方法将100例HP感染消化性溃疡按随机数字表法分为治疗组(埃索美拉唑+克拉霉素+阿莫西林)50例和对照组(奥美拉唑+克拉霉素+阿莫西林)50例,治疗1个疗程后,观察患者溃疡愈合和HP根除情况。结果与对照组比较,治疗组愈合率、总有效率明显高于对照组(P<0.05);治疗组HP根除率差异无统计学意义(P>0.05),但治疗组HP根除率高于对照组。结论以埃索美拉唑+克拉霉素+阿莫西林三联疗法在治疗消化性溃疡的愈合率、有效率方面明显优于奥美拉唑+克拉霉素+阿莫西林三联疗法,HP根除率高于奥美拉唑三联疗法,值得临床推广。
Objective To observe the clinical efficacy of esomeprazole triple therapy in eradicating Helicobacter pylori (HP) infection of peptic ulcer (PU). Methods 100 cases of HP-infected peptic ulcer were randomly divided into treatment group (esomeprazole + clarithromycin + amoxicillin) 50 cases and control group (omeprazole + clarithromycin + amo Xilin) 50 cases, after a course of treatment, the observation of patients with ulcer healing and HP eradication. Results Compared with the control group, the healing rate and total effective rate in the treatment group were significantly higher than those in the control group (P <0.05). There was no significant difference in the eradication rate of HP between the treatment group and the control group (P> 0.05) group. Conclusions The triple therapy of esomeprazole + clarithromycin + amoxicillin is superior to omeprazole + clarithromycin + amoxicillin triple therapy in the treatment of peptic ulcer in terms of the healing rate and efficiency, and the HP eradication rate Higher than omeprazole triple therapy, it is worth clinical promotion.